So much for July and August being dead months in the biopharma sector. Infinity Pharma (NASDAQ: INFI) has released a string of updates that promise to completely alter the trajectory of the company compared to just a couple quarters ago. Entering 2012, Infinity’s lead program was the hedgehog inhibitor saridegib (IPI-926, background info here). Unfortunately the company […]
INFI – Pivoting From Hedgehog to PI3K
Failed trials can’t hold this stock down. In recent months, the hedgehog pathway inhibitor saridegib (also known as IPI-926) – once the company’s leading pipeline candidate – has crashed out of pancreatic cancer, chondrosarcoma and myelofibrosis trials, but the stock has since broken out to new 52-week highs. Following these disappointments, Infinity has discontinued all […]
INFI – Update on Infinity Pharmaceuticals
For the second time this year, on June 18th, 2012 Infinity Pharma held a conference call to discuss their hedgehog pathway inhibitor drug candidate saridegib (IPI-926). Unfortunately, as in January, the news was not good. After the data monitoring committee stopped the saridegib plus gemcitabine trial in January, Infinity decided to proceed with additional trials in […]
Updates from the Jefferies Global Healthcare Conference
The 2012 Jefferies Global Healthcare Conference was held June 4-7, 2012. You can access the full schedule and webcasts here. I’ll provide brief updates on the presentations by several companies in this post. Keep your eye on the Chimera Proprietary Calendar for all upcoming investor meetings, with links to the webcasts and schedules. Note that […]
Heat Shock Protein 90 (HSP90) inhibitors: Back in the spotlight – Part 1
Heat Shock Protein 90 (HSP90) was originally proposed as a cancer drug target in the 1990s, though no drug in this class have ever successfully completed a randomized clinical trial, let alone achieve regulatory approval. Despite repeated setbacks, HSP90 inhibitors are poised to find a significant niche in the evolving cancer treatment landscape. We will […]
Updates from the Citi Global Healthcare Conference
The annual Citi Global Healthcare Conference was held February 27-29, 2012, and as always we listened in on the webcasts to identify key takeaways for Chimera Research Group shareholders. These write-ups may be brief due to overlap with comments at other recent investor conferences – see links below. Amarin $AMRN (Leerink Swann notes – company overview) “We […]
Quick updates from BIO CEO & Investor Conference
The annual BIO CEO & Investor conference was held February 13-14th in New York, a key forum for small biotech companies, especially those that do not receive an invite to the JP Morgan conference in January. Below are some very quick notes from a number of presentations; be sure to note some changes in the […]
INFI – Hedgehog inhibitor fails phase 2 trial in pancreatic cancer
Infinity Pharma $INFI announced on January 27th that it was halting a randomized phase 2 trial of the Hedgehog inhibitor saridegib (IPI-926) in metastatic pancreatic cancer, sending the stock down by about 40% to around $6.00 (~$160m market cap). I’ll recap what happened and what is next for INFI based today’s conference call as well […]
Biotech catalysts at two upcoming medical conferences
We want to take a moment to highlight two upcoming oncology focused medical conferences that will showcase data that represent potential catalysts for several biotech companies we’re tracking. First up, we have the 2012 ASCO Gastrointestinal Cancers Symposium from January 19-21, 2012. This conference will be focused on developments in the treatment of cancers of […]
